Open AccessOutcomes of patients with IDH1-mutant relapsed or refractory acute myeloid leukemia receiving ivosidenib who proceeded to hematopoietic stem cell transplant
Author(s) -
Courtney D. DiNardo,
Eytan M. Stein,
Arnaud Pigneux,
Jessica K. Altman,
Robert H. Collins,
Harry P. Erba,
Justin M. Watts,
Geoffrey L. Uy,
Thomas Winkler,
Hongfang Wang,
Sung Choe,
Hua Liu,
Bin Wu,
Stephanie M. Kapsalis,
Gail J. Roboz,
Stéphane de Botton
Publication year - 2021
Publication title -
leukemia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.539
H-Index - 192
eISSN - 1476-5551
pISSN - 0887-6924
DOI - 10.1038/s41375-021-01229-x
Subject(s) - myeloid leukemia , stem cell , refractory (planetary science) , hematopoietic stem cell transplantation , idh1 , haematopoiesis , medicine , salvage therapy , hematopoietic stem cell , cancer research , myeloid , transplantation , oncology , mutant , chemotherapy , biology , gene , genetics , astrobiology , biochemistry